Immuneering Corporation Comprehensive Income
Immuneering Corporation (IMRX) reported Comprehensive Income of -$17.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- Immuneering Corporation comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$17.44M.
- Immuneering Corporation comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$13.78M.
- Immuneering Corporation comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$11.50M.
- Immuneering Corporation comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$14.96M.
- Immuneering Corporation comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$55.94M.
- Immuneering Corporation comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$61.04M.
- Immuneering Corporation comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$53.44M.
- Immuneering Corporation comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$50.49M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$17.44M 10-Q · filed 2026-08-05 | -$31.22M 10-Q · filed 2026-08-05 | -$42.72M derived: sum of 3 quarters · filed 2026-08-05 | -$57.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$13.78M 10-Q · filed 2026-05-15 | -$25.28M derived: sum of 2 quarters · filed 2026-05-15 | -$40.25M derived: sum of 3 quarters · filed 2026-05-15 | -$54.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$11.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$26.46M derived: sum of 2 quarters · filed 2026-03-06 | -$40.90M derived: sum of 3 quarters · filed 2026-08-05 | -$55.94M 10-K · filed 2026-03-06 |
| 2025-09-30 | -$14.96M 10-Q · filed 2025-11-12 | -$29.40M derived: sum of 2 quarters · filed 2026-08-05 | -$44.44M 10-Q · filed 2025-11-12 | -$62.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$14.43M 10-Q · filed 2026-08-05 | -$29.48M 10-Q · filed 2026-08-05 | -$47.54M derived: sum of 3 quarters · filed 2026-08-05 | -$62.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$15.05M 10-Q · filed 2026-05-15 | -$33.11M derived: sum of 2 quarters · filed 2026-05-15 | -$47.69M derived: sum of 3 quarters · filed 2026-05-15 | -$61.77M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$18.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$32.65M derived: sum of 2 quarters · filed 2026-03-06 | -$46.73M derived: sum of 3 quarters · filed 2026-03-06 | -$61.04M 10-K · filed 2026-03-06 |
| 2024-09-30 | -$14.59M 10-Q · filed 2025-11-12 | -$28.67M derived: sum of 2 quarters · filed 2025-11-12 | -$42.98M 10-Q · filed 2025-11-12 | -$58.07M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$14.08M 10-Q · filed 2025-08-13 | -$28.39M 10-Q · filed 2025-08-13 | -$43.48M derived: sum of 3 quarters · filed 2025-08-13 | -$56.06M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$14.31M 10-Q · filed 2025-05-05 | -$29.40M derived: sum of 2 quarters · filed 2025-05-05 | -$41.99M derived: sum of 3 quarters · filed 2025-05-05 | -$54.18M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | -$15.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$27.68M derived: sum of 2 quarters · filed 2025-03-20 | -$39.87M derived: sum of 3 quarters · filed 2025-03-20 | -$53.44M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$12.59M 10-Q · filed 2024-11-13 | -$24.78M derived: sum of 2 quarters · filed 2024-11-13 | -$38.35M 10-Q · filed 2024-11-13 | -$51.49M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$12.19M 10-Q · filed 2024-08-06 | -$25.77M 10-Q · filed 2024-08-06 | -$38.90M derived: sum of 3 quarters · filed 2024-08-06 | -$51.70M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$13.57M 10-Q · filed 2024-05-07 | -$26.71M derived: sum of 2 quarters · filed 2024-05-07 | -$39.51M derived: sum of 3 quarters · filed 2024-05-07 | -$51.05M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$13.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$25.94M derived: sum of 2 quarters · filed 2024-03-01 | -$37.48M derived: sum of 3 quarters · filed 2024-03-01 | -$50.49M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$12.81M 10-Q · filed 2023-11-09 | -$24.35M derived: sum of 2 quarters · filed 2023-11-09 | -$37.36M 10-Q · filed 2023-11-09 | -$48.19M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$11.54M 10-Q · filed 2023-08-03 | -$24.56M 10-Q · filed 2023-08-03 | -$35.38M derived: sum of 3 quarters · filed 2023-08-03 | -$43.92M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$13.01M 10-Q · filed 2023-05-04 | -$23.84M derived: sum of 2 quarters · filed 2023-05-04 | -$32.38M derived: sum of 3 quarters · filed 2023-05-04 | -$40.37M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$10.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$19.37M derived: sum of 2 quarters · filed 2023-03-06 | -$27.36M derived: sum of 3 quarters · filed 2023-03-06 | -$33.58M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$8.54M 10-Q · filed 2022-11-10 | -$16.53M derived: sum of 2 quarters · filed 2022-11-10 | -$22.76M 10-Q · filed 2022-11-10 | -$28.59M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$7.99M 10-Q · filed 2022-08-10 | -$14.22M 10-Q · filed 2022-08-10 | -$20.05M derived: sum of 3 quarters · filed 2022-08-10 | -$24.45M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$6.23M 10-Q · filed 2022-05-10 | -$12.07M derived: sum of 2 quarters · filed 2022-05-10 | -$16.46M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$5.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$10.24M derived: sum of 2 quarters · filed 2022-03-10 | -$17.04M 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$4.40M 10-Q · filed 2021-11-09 | -$11.20M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |